Filing Details

Accession Number:
0001104659-13-071668
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-09-23 16:42:15
Reporting Period:
2013-09-19
Filing Date:
2013-09-23
Accepted Time:
2013-09-23 16:42:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1386858 Hyperion Therapeutics Inc HPTX Pharmaceutical Preparations (2834) 611512713
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1343244 P L Vii-B Partners Capital Highland C/O Highland Capital Partners,
One Broadway, 16Th Floor
Cambridge MA 02142
No No Yes No
1343673 Highland Capital Partners Vii-C Lp C/O Highland Capital Partners,
One Broadway, 16Th Floor
Cambridge MA 02142
No No Yes No
1343678 Highland Capital Partners Vii Lp C/O Highland Capital Partners,
One Broadway, 16Th Floor
Cambridge MA 02142
No No Yes No
1357840 Partnership Limited Vii Fund Entrepreneurs Highland C/O Highland Capital Partners,
One Broadway, 16Th Floor
Cambridge MA 02142
No No Yes No
1554026 Highland Management Partners Vii, Llc C/O Highland Capital Partners,
One Broadway, 16Th Floor
Cambridge MA 02142
No No Yes No
1554027 Partnership Limited Vii Partners Management Highland C/O Highland Capital Partners,
One Broadway, 16Th Floor
Cambridge MA 02142
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2013-09-19 894 $25.93 1,235,364 No 4 S Indirect See Footnotes
Common Stock Disposition 2013-09-19 217 $25.93 299,348 No 4 S Indirect See Footnotes
Common Stock Disposition 2013-09-19 315 $25.93 435,946 No 4 S Indirect See Footnotes
Common Stock Disposition 2013-09-19 28 $25.93 38,699 No 4 S Indirect See Footnotes
Common Stock Disposition 2013-09-20 2,643 $25.81 1,232,721 No 4 S Indirect See Footnotes
Common Stock Disposition 2013-09-20 641 $25.81 298,707 No 4 S Indirect See Footnotes
Common Stock Disposition 2013-09-20 933 $25.81 435,013 No 4 S Indirect See Footnotes
Common Stock Disposition 2013-09-20 83 $25.81 38,616 No 4 S Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
Footnotes
  1. The securities are held by Highland Capital Partners VII Limited Partnership ("HCP VII"). Highland Management Partners VII, LLC ("HMP VII LLC") is the general partner of Highland Management Partnership VII Limited Partnership ("HMP VII LP"), which is the general partner of HCP VII. Each of HMP VII LP and HMP VII LLC disclaims beneficial ownership of all shares held by HCP VII except to the extent, if any, of such entity's pecuniary interest therein.
  2. The securities are held by Highland Capital Partners VII-B Limited Partnership ("HCP VII-B"). HMP VII LP is the general partner of HCP VII-B. Each of HMP VII LP and HMP VII LLC disclaims beneficial ownership of all shares held by HCP VII-B except to the extent, if any, of such entity's pecuniary interest therein.
  3. The securities are held by Highland Capital Partners VII-C Limited Partnership ("HCP VII-C"). HMP VII LP is the general partner of HCP VII-C. Each of HMP VII LP and HMP VII LLC disclaims beneficial ownership of all shares held by HCP VII-C except to the extent, if any, of such entity's pecuniary interest therein.
  4. The securities are held by Highland Entrepreneurs' Fund VII Limited Partnership ("HEF VII"). HMP VII LP is the general partner of HEF VII. Each of HMP VII LP and HMP VII LLC disclaims beneficial ownership of all shares held by HEF VII except to the extent, if any, of such entity's pecuniary interest therein.
  5. This price represents the weighted average of sales ranging from $25.75 to $26.06. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  6. This price represents the weighted average of sales ranging from $25.75 to $25.98. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.